NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/18/2025
Back to search
Official data from USPTO
WAVE LIFE SCIENCES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
02/18/2025
Classification
Registered
Trademark type
Combined
Nice classes
5, 42
Filing date
01/09/2024
Registration date
02/18/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/18/2025
Last transaction
02/18/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
99
Owner location
Singapore, SG
Examiner
PULVERMACHER, TASHA
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized word "WAVE" appearing in larger text above the smaller stylized words "LIFE SCIENCES".
Holders and representatives
Holders
Wave Life Sciences Ltd.
Representatives
Sara M. Bauer Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Nucleic acid sequences and chemical reagents for medical purposes; pharmaceutical preparations for the treatment of genetic diseases and disorders; genetic medicines for the treatment of diseases and disorders with known genetic causecomponent and disease states resulting from gene expression and genetic sequence; nucleic acid therapeutic agents for the treatment of Huntington's diseaseDuchenne muscular dystrophyalpha-1 antitrypsin deficiency for medical purposes; pharmaceutical preparations for the preventiondiagnosistreatment of metaboliccardiometabolicendocrinemusculoskeletalcardiovascularcardiopulmonaryrenalgenitourinaryoncologicalhepatologicalophthalmicrespiratoryneurologicalneurodegenerativegastrointestinalhormonalinflammatorydermatologicalpsychiatricautoimmuneimmune system related diseases and disorders
Class 42
Research and development in the fields of pharmaceuticalsgeneticstherapeuticsdrug formulation and delivery; scientific research; scientific research in the fields of pharmaceuticalsmedicinenucleic acid therapeutics; researchdevelopmenttesting services in the field of nucleic acid therapeutics for medical and scientific applications; medical research; laboratory research services relating to pharmaceuticals
Publications
History of USPTO decisions and trademark events.
15 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/18/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/31/2024
PUBO
PUBLISHED FOR OPPOSITION
12/31/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/25/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/06/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/06/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/07/2024
GNRT
NON-FINAL ACTION E-MAILED
08/07/2024
CNRT
NON-FINAL ACTION WRITTEN
08/07/2024
DOCK
ASSIGNED TO EXAMINER
08/05/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/28/2024
NWAP
NEW APPLICATION ENTERED
01/09/2024
Continuous trademark protection
Get notified about every new filing that threatens WAVE LIFE SCIENCES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.